Gilead’s Experimental Hepatitis C Drug Cured 88% Post-Therapy

Gilead Sciences Inc.’s experimental hepatitis C drug cleared the virus in 88 percent of patients four weeks after treatment ended in a study, the company said today.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.